Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Other Operating Expenses (2016 - 2025)

Amicus Therapeutics filings provide 15 years of Other Operating Expenses readings, the most recent being $1.9 million for Q4 2025.

  • On a quarterly basis, Other Operating Expenses changed N/A to $1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.2 million, a N/A change, with the full-year FY2023 number at -$2.6 million, down 139.61% from a year prior.
  • Other Operating Expenses hit $1.9 million in Q4 2025 for Amicus Therapeutics, up from $1.9 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $3.6 million in Q2 2025 to a low of -$3.3 million in Q3 2021.
  • Median Other Operating Expenses over the past 4 years was -$337000.0 (2023), compared with a mean of -$67533.3.
  • Biggest five-year swings in Other Operating Expenses: plummeted 273.71% in 2021 and later surged 352.23% in 2022.
  • Amicus Therapeutics' Other Operating Expenses stood at -$1.7 million in 2021, then grew by 8.65% to -$1.6 million in 2022, then decreased by 25.95% to -$2.0 million in 2023, then surged by 195.09% to $1.9 million in 2025.
  • The last three reported values for Other Operating Expenses were $1.9 million (Q4 2025), $1.9 million (Q3 2025), and $3.6 million (Q2 2025) per Business Quant data.